Zai Lab Ltd.

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China

AdaptHealth Corp

iRhythm Technologies

Retractable Technologies

Sanara MedTech Inc.

These companies made millions by developing equipment for life-saving care, and enriched shareholders too.

These Were the 5 Best Medical Device Stocks of 2020

SHANGHAI and SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 11:40 a.m. EST.

Zai Lab Announces Upcoming Presentation at 39th Annual J.P. Morgan Healthcare Conference

SHANGHAI and SAN FRANCISCO, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced that ZEJULA® has been included in the updated National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA). ZEJULA (niraparib) is an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor with national Category 1 designation. It has been included in the NRDL as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List

- Zai Lab to lead development and commercialization of CLN-081 in Greater China

Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China

SHANGHAI and SAN FRANCISCO, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited's (NASDAQ: ZLAB; HKEX: 9688) partner MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal-antibody-based therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved MARGENZA, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. MARGENZA is being further developed by MacroGenics for the treatment of advanced gastric cancer, with support by Zai Lab in Greater China. The approval in breast cancer in the U.S. was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial.

Zai Lab Partner MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer

BioNTech SE

CRISPR Therapeutics

Denali Therapeutics

Mirati Therapeutics

Novavax

Seagen

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

7 Biotech Stocks To Buy Beyond Covid Vaccine Plays

SHANGHAI and SAN FRANCISCO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced the appointment of Alan Sandler, M.D., to the newly created position of President, Head of Global Development, Oncology, where he will lead global oncology development and related enabling functions to support the Company's development activities. Dr. Sandler was most recently the Senior Vice President and Global Head of Product Development Oncology at Genentech, a member of the Roche Group. He will report to Dr. Samantha Du, Chief Executive Officer, and serve on the executive team.

Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology

SHANGHAI and SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited's (NASDAQ: ZLAB; HKEX: 9688) partner Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 2 FIGHT trial. The trial compared bemarituzumab (FPA144), a potential first-in-class targeted therapy, in combination with mFOLFOX6 chemotherapy to placebo in combination with mFOLFOX6 in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+), HER2-negative front-line advanced gastric or gastroesophageal junction (GEJ) cancer.

Zai Lab Partner Five Prime Therapeutics Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric or Gastroesophageal Junction Canc

Labcorp Holdings Inc

QuidelOrtho Corp

The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio earlier this week.

Vanguard Health Care Fund Adds 3 Positions to Portfolio

CASI Pharmaceuticals

Incyte

Ocular Therapeutix

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint receptor inhibitor from Sweden's BioInvent in a $95 million deal.

Week In Review: CStone Out-Licenses Ex-China Rights To 2 Immunotherapies In $1.3 Billion Deal

SHANGHAI and SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced dosing of the first patient in China in the global POD1UM-101 study evaluating retifanlimab in patients with previously treated, microsatellite instability-high endometrial cancer.

Zai Lab Announces First Patient Dosed in China in a Potentially Registrational Study of Retifanlimab in Patients with Endometrial Cancer

SHANGHAI and SAN FRANCISCO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, today announced that management from Zai Lab will present at the following upcoming virtual investor conferences in November. Details are as follows:

Zai Lab Announces Upcoming Presentations in November Investor Conferences

Corvus Pharmaceuticals

10X Genomics

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Week In Review: $1.5 Billion Total In Week's China Deals

SHANGHAI and SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced full exercise of the over-allotment option.

Zai Lab Announces Full Exercise of the Over-allotment Option

SHANGHAI and SAN FRANCISCO, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient in Greater China in the global MAHOGANY study evaluating margetuximab, an investigational, Fc-optimized monoclonal antibody targeting HER2, in combination with a checkpoint inhibitor, with or without chemotherapy, as a potential first-line treatment for patients with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer.

Zai Lab Announces First Patient Dosed in Greater China in the Global Phase 2/3 MAHOGANY Study of Margetuximab in Gastric and Gastroesophageal Junction Cancer

SHANGHAI and SAN FRANCISCO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial stage biopharmaceutical company, announced dosing of the first patient in China in the global Phase 3 POD1UM-304 study evaluating retifanlimab, an investigational anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with first-line metastatic non-small-cell lung cancer (NSCLC).

Zai Lab Announces First Patient Dosed in China in a Global Phase 3 Study of Retifanlimab in Patients with NSCLC

Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion.

Week In Review: Zai Lab Completes Second Listing With $761 Million HK IPO

SHANGHAI and SAN FRANCISCO, Sept.  28, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9688” and the closing of its previously-announced Hong Kong secondary listing (the “Hong Kong Secondary Listing”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering,” and together with the International Offering, the “Offering”). The final offer price for both the International Offering and the Hong Kong Public Offering (the “Offer Price”) has been set at HK$562.00 per Share. Based on the ratio of one (1) ordinary shares per Nasdaq-listed American depositary share (“ADS”), the Offer Price translates to approximately US$72.52 per ADS. The Company had also granted the international underwriters an over-allotment option, exercisable from September 22, 2020 until 30 days thereafter, to require the Company to issue up to an additional 1,584,600 new Shares at the Offer Price.

Zai Lab Announces Closing of Hong Kong Secondary Listing

SHANGHAI, Sept. 27, 2020 /PRNewswire/ -- Qiming's portfolio company Zai Lab (SEHK:9688, NASDAQ:ZLAB), an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today. In this secondary listing, the issue price...

Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX

SHANGHAI and SAN FRANCISCO, Sept.  22, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced the pricing of the Hong Kong secondary listing (the “Hong Kong Secondary Listing”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) which comprises an international offering (the “International Offering”) and a Hong Kong public offering (the “Hong Kong Public Offering”). The final offer price for both the International Offering and the Hong Kong Public Offering (the “Offer Price”) has been set at HK$562.00 per Share. Based on the ratio of one (1) ordinary shares per Nasdaq-listed American depositary share (“ADS”), the Offer Price translates to approximately US$72.52 per ADS. The Company has set the abovementioned offer price by taking into consideration, among other factors, the closing price of the ADSs on September 21, 2020 (the latest trading day before pricing). Subject to approval from The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”), the Shares are expected to begin trading on the Main Board of the Hong Kong Stock Exchange on September 28, 2020 under the stock code “9688” The Hong Kong Secondary Listing is expected to close on the same day, subject to customary closing conditions.

Zai Lab Announces Pricing of Hong Kong Secondary Listing

Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO

SHANGHAI and SAN FRANCISCO, Sept.  19, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced detailed positive results from the NORA study, the Phase 3 randomized, double-blind, placebo-controlled study of ZEJULA (niraparib) as a maintenance therapy in Chinese patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (collectively termed as ovarian cancer) who are in a complete or partial response to platinum-based chemotherapy.

Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian c

SHANGHAI and SAN FRANCISCO, Sept.  16, 2020  (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the “Hong Kong Public Offering”), which forms part of the global offering (the “Offering”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9688”.

Zai Lab Launches Hong Kong Secondary Listing

Du leads Shanghai-based pharma company Zai Lab, whose $6 billion market cap has increased threefold since its IPO valuation on Nasdaq in 2017.

Samantha Du: Meet The Woman Shaking Up China’s Pharmaceutical Market

News for Zai Lab Ltd. Stock (ZLAB)